Caris Life Sciences, Inc. (CAI) Insider Trading Activity

NASDAQ$19.05
Market Cap
$5.38B
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
307 of 881
Rank in Industry
179 of 504

CAI Insider Trading Activity

CAI Median Price and Trade Amounts History Chart

Statistics of Insider Transactions

Amount of Insider Buys and Sells

Buys
$110,333
2
67
Sells
$1,654,461
1
33

Related Transactions

Denton John RusselSee Remarks
1
$100,793
0
$0
$100,793
Spetzler David BaxleyPresident
1
$9,540
0
$0
$9,540
Power Luke ThomasSee Remarks
0
$0
1
$1.65M
$-1.65M

About Caris Life Sciences, Inc.

Caris Life Sciences, Inc., an artificial intelligence TechBio company, provides molecular profiling services in the United States and internationally. It develops and commercializes solutions to transform healthcare using molecular information, and machine learning algorithms. The company's molecular profiling services portfolio includes MI Profile, a tissue-based molecular profiling solution; and Caris Assure, a blood-based molecular profiling solution for cancer treatment. It also offers pharma research and development services comprising laboratory delivery, strategic data, and research services to biopharmaceutical customers. The company was founded in 2008 and is headquartered in Irving, Texas.

Insider Activity of Caris Life Sciences, Inc.

Over the last 12 months, insiders at Caris Life Sciences, Inc. have bought $110,333 and sold $1.65M worth of Caris Life Sciences, Inc. stock.

On average, over the past 5 years, insiders at Caris Life Sciences, Inc. have bought $110,333 and sold $1.65M worth of stock each year.

Highest buying activity among insiders over the last 12 months: Denton John Russel (See Remarks) — $100,793. Spetzler David Baxley (President) — $9,540.

The last purchase of 400 shares for transaction amount of $9,540 was made by Spetzler David Baxley (President) on 2025‑11‑07.

List of Insider Buy and Sell Transactions, Caris Life Sciences, Inc.

2025-12-11SalePower Luke ThomasSee Remarks
62,250
0.0204%
$26.58
$1.65M
-5.80%
2025-11-07PurchaseSpetzler David BaxleyPresident
400
0.0001%
$23.85
$9,540
-1.78%
2025-11-07PurchaseDenton John RusselSee Remarks
4,184
0.0012%
$24.09
$100,793
-1.78%
2019-03-29SaleSawka Garydirector
10,000
0.0029%
$23.23
$232,300
2019-02-27PurchaseGarcia VictorPresident and CEO
100
<0.0001%
$22.74
$2,274
2019-02-26PurchaseGarcia VictorPresident and CEO
10,508
0.0029%
$22.24
$233,698
2018-06-01PurchaseGarcia VictorPresident and CEO
10,000
0.003%
$24.25
$242,480
2018-05-14PurchaseGarcia VictorPresident and CEO
2,079
$25.00
$51,975
2018-05-11PurchaseGarcia VictorPresident and CEO
9,921
$25.00
$248,025
2018-05-01SaleOgawa Family Trust10 percent owner
1.23M
0.3453%
$22.81
$27.95M
2018-05-01SaleOgawa Andrew
1.23M
0.3453%
$22.81
$27.95M
2018-02-20SaleOgawa Family Trust10 percent owner
1.25M
0.3333%
$21.58
$26.98M
2017-12-07SaleREMINGTON DAVID Gdirector
4,360
0.0018%
$33.10
$144,316
2017-12-06SaleREMINGTON DAVID Gdirector
3,200
0.0013%
$31.91
$102,112
2017-12-05SaleREMINGTON DAVID Gdirector
4,040
0.0016%
$32.68
$132,027
2017-11-10SaleGarcia VictorPresident and CEO
27,836
0.0124%
$36.12
$1.01M
2017-11-09SaleGarcia VictorPresident and CEO
13,571
0.006%
$36.06
$489,370
2017-11-02SaleSawka Garydirector
3,000
0.0014%
$36.50
$109,500
2017-10-31SaleSawka Garydirector
3,365
0.0015%
$37.00
$124,505
2017-10-27SaleCutino CamilleVP, Operations and HR
39,311
0.0179%
$36.91
$1.45M
Total: 70
*Gray background shows transactions not older than one year
*Some uncertain data for Preferred Stock share type transactions are shown in italics; for actual data please follow the link

CAI Institutional Investors: Active Positions

Increased Positions140+106.06%53M+46.57%
Decreased Positions58-43.94%20M-17.45%
New Positions76New27MNew
Sold Out Positions27Sold Out9MSold Out
Total Postitions214+62.12%146M+29.12%

CAI Ownership Change vs Market

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders

Financial Ratios

Summary
Comparison with Competitors

Price to Earnings

Price/Earnings to Growth

Price to Sales

Price to Book

Price/Free Cash Flow

Analyst Recommendations

Analyst Price Targets

Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.